For more than a decade, Ncardia has been pioneering innovations in human induced pluripotent stem cells (iPSC).
NETRI is an industrial start-up developing innovative technologies for the pharmaceutical industry. Its patented organs-on-chip technologies allow the creation of standardized and predictive human in vitro models.
Ananda Devices is a biotech company offering high throughput organ on-a-chip technologies such as neurons on-a-chip to accelerate R&D in pharmaceutical, food and cosmetic (PFC) industries
Hesperos is accelerating drug discovery by providing safety and efficacy testing services using its Human-on-a-Chip, microphysiological system. This breakthrough technology enables unprecedented preclinical insight bringing better therapies to patients faster without the need for animal testing.
Curi’s suite of human iPSC-derived products and services enable scientists to build more mature and predictive human iPSC-derived tissues—with a focus on cardiac, musculoskeletal, and neuromuscular models—for the discovery, safety testing, and efficacy testing of new drugs in development.
Mimetas develops high-throughput healthy and diseased organ-on-a-chip models in the OrganoPlate®, a screening-compatible microfluidics platform that supports the recreation of native tissue structures, and their interaction with compounds, signaling factors, disease triggers, and co-cultured cell types.